Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOLANT: Lidocaine in Thyroid Surgery
NCT04574947Phase 4Completed
- Sponsor
- Saint Petersburg State University
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Lidocaine Hydrochloride Injection, without epinephrine in thyroid neoplasm and Parathyroid neoplasm (3 arms), sponsored by Saint Petersburg State University. Primary endpoint: Quality of recovery 40 questionnaire at 1 day. Started Jan 2021; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
thyroid neoplasmParathyroid neoplasm
Beyond the preview
Go deeper on NCT04574947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574947.